1，25-二羟维生素D3治疗糖尿病肾病疗效观察
Effect of 1,25-dihydroxyvitamin D3 in the treatment of diabetic nephropathy

李艳丽.1，25-二羟维生素D3治疗糖尿病肾病疗效观察[J].内科急危重症杂志,2019,25(1):26-28

扫码阅读全文

DOI：10.11768/nkjwzzzz20190108

英文关键词:

基金项目:

作者	单位	E-mail
李艳丽	十堰市人民医院(湖北医药学院附属人民医院)	yuxiongjie52@163.com

摘要点击次数: 1793

全文下载次数: 2742

中文摘要:

目的：探讨1，25-二羟维生素D3治疗糖尿病肾病(DN)的疗效。方法：将60例DN患者随机分为试验组和对照组,每组30例。2组患者均接受常规降糖治疗，对照组患者口服厄贝沙坦150～300mg/d；试验组患者口服厄贝沙坦150～300mg/d，联合口服阿法骨化醇0.25μg，1次/d。记录并比较2组患者治疗前、后血糖化血红蛋白、肌酐等水平。结果：治疗3个月后试验组肌酐、尿N-乙酰-β-氨基葡萄糖苷酶、尿蛋白、血转化生长因子β1均显著低于对照组 (均P<0.05)。结论：1,25-二羟维生素D3对DN患者有肾保护作用。

英文摘要:

Objective: To study the effects of 1,25- dihydroxyvitamin D3 in the treatment of diabetic nephropathy (DN). Methods: Sixty patients with DN were selected and randomly divided into experimental group (EG, n=30) and control group (CG, n=30). All patients were given the routine hypoglycemic treatment. The control group was treated with irbesartan (150 to 300mg/day). The experimental group was treated with irbesartan (150 to 300mg/day), combined with oral administration of alfacalcidol (0.25μg, once every day). The blood HbA1c, serum creatinine (Scr) and other biochemical test results before and after the treatement were recorded. Results: After treatment, the Scr, NAG, UPRO and blood TGF-β1 in the experimental group were significantly lower than those in the control group (P<0.05). Conclusion: 1,25-dihydroxyvitamin D3 in the treatment of DN has the role to protect the kidney function.